Counseling about hepatitis C transmission and alcohol consumption and treatment with medications that are simpler, faster and more effective than ever. All possible in primary care. Take the post-test to claim your credit.
Learn the basics of hepatitis C, including how the virus is transmitted, who to screen for the infection, and why screening is critical to interrupting the epidemic of hepatitis C and its life-threatening consequences. Take the post-test to claim your credit.
Hep C (HCV) treatment is easier and more effective, than ever. Cure is almost always expected when treated—even current drug users—so learn how you can cure HCV and help prevent re-infection, liver damage, cancer and death. Take the post-test to claim your credit.
Hepatitis C is a huge killer, but it doesn’t have to be. Cure is possible, even among drug users. Be part of the cure by learning what is involved in screening (hint: not much) and how screening can save lives. Take the post-test to claim your credit.
Volume 4, Issue 10.
Drs Kenneth Sherman, MD, PhD and Nadeem Anwar, MD cover the important topic of New Approaches to the Diagnosis and Management of Chronic HBV Infection in the format of case-study scenarios for the clinical practice.
To read a companion newsletter click here.
Volume 4, Issue 8, Part 3.
Raymond T. Chung, MD from Harvard Medical School interviews Dr. David Wyles from the University of California San Diego about his presentation: Sofosbuvir/Velpatasivr Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study, presented at the April 2016 EASL meeting.
Volume 4, Issue 8, Part 2.
Raymond T. Chung, MD from Harvard Medical School interviews Dr. Michael Charlton from Intermountain Medical Center about his abstract: Resistance Analyses for Ledipasvir/Sofosbuvir-Containing Regimens in Patients Infected with Chronic HCV Who Have Advanced Liver Disease or are Post Liver Transplant(SOLAR-1 & 2 Studies), presented at the April 2016 EASL meeting.
Volume 4, Issue 8, Part 1.
Raymond T. Chung, MD from Harvard Medical School interviews Dr. Eric Lawitz from the University of Texas Health Science Center about his presentation: High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals presented at the April 2016 EASL meeting.